NCT02834663View on ClinicalTrials.gov

Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

December 31, 2019

Conditions
Nonproliferative Diabetic Retinopathy
Interventions
DRUG

Lucentis

Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.

All Listed Sponsors
collaborator

Novartis Korea Ltd.

INDUSTRY

lead

Wonkwang University Hospital

OTHER

NCT02834663 - Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter